{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:10:01Z","timestamp":1781147401154,"version":"3.54.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T00:00:00Z","timestamp":1396483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0092494","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T16:38:35Z","timestamp":1396543115000},"page":"e92494","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":61,"title":["Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies"],"prefix":"10.1371","volume":"9","author":[{"given":"Derek J.","family":"Nunez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Gillmor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Apseloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Atiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Corsino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.03.012","article-title":"Unraveling the science of incretin biology","volume":"122","author":"MA Nauck","year":"2009","journal-title":"Am J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"DJ Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tips.2010.10.003","article-title":"Emerging therapies in the treatment of \u2018diabesity\u2019: beyond GLP-1","volume":"32","author":"G Tharakan","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"CF Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/en.2005-0972","article-title":"Attenuated peptide YY release in obese subjects is associated with reduced satiety","volume":"147","author":"CW le Roux","year":"2006","journal-title":"Endocrinology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/13543784.16.4.533","article-title":"Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes","volume":"16","author":"CF Deacon","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"ref7","first-page":"336","article-title":"Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes","volume":"17","author":"E Mannucci","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0006-291X(02)02565-2","article-title":"Enhanced secretion of glucagon-like peptide 1 by biguanide compounds","volume":"298","author":"N Yasuda","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"GA Herman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2174\/138955708786369546","article-title":"Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview","volume":"8","author":"S Correia","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"A Natali","year":"2006","journal-title":"Diabetologia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.metabol.2012.06.010","article-title":"GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function","volume":"62","author":"S Odori","year":"2013","journal-title":"Metabolism"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/13543784.2012.657797","article-title":"The therapeutic potential of GPR119 agonists for type 2 diabetes","volume":"21","author":"T Ohishi","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/clpt.2011.169","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects","volume":"90","author":"LB Katz","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","unstructured":"Fang J, Tang J, Carpenter AJ, Peckham G, Conlee CR, et al. (2008) Preparation of piperidine derivatives as GPR119 agonists for treating metabolic disorders. United States patent PCT\/US2007\/086434"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-12-381517-0.00016-3","article-title":"GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders","volume":"84","author":"U Shah","year":"2010","journal-title":"Vitam Horm"},{"key":"ref17","unstructured":"International Conference on Harmonisation (1996) ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. Version 10."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/00498254.2012.739719","article-title":"Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design","volume":"43","author":"JW Polli","year":"2013","journal-title":"Xenobiotica"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.2337\/diabetes.54.11.3265","article-title":"Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals","volume":"54","author":"MC Dalla","year":"2005","journal-title":"Diabetes"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1113\/jphysiol.2008.164269","article-title":"The role of peptide YY in appetite regulation and obesity","volume":"587","author":"E Karra","year":"2009","journal-title":"J Physiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1463-1326.2009.01167.x","article-title":"Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus","volume":"12","author":"K Aaboe","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3\u201336","volume":"349","author":"RL Batterham","year":"2003","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1515\/hsz-2013-0123","article-title":"Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors","volume":"394","author":"S Babilon","year":"2013","journal-title":"Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jada.2009.12.023","article-title":"Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review","volume":"110","author":"LM Beckman","year":"2010","journal-title":"J Am Diet Assoc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.sla.0000183349.16877.84","article-title":"Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters","volume":"243","author":"CW le Roux","year":"2006","journal-title":"Ann Surg"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/SLA.0b013e3180caa3e3","article-title":"Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass","volume":"246","author":"CW le Roux","year":"2007","journal-title":"Ann Surg"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s11695-012-0738-5","article-title":"Lower Ghrelin Levels and Exaggerated Postprandial Peptide-YY, Glucagon-Like Peptide-1, and Insulin Responses, After Gastric Fundus Resection, in Patients Undergoing Roux-en-Y Gastric Bypass: A Randomized Clinical Trial","volume":"22","author":"A Chronaiou","year":"2012","journal-title":"Obes Surg"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.coph.2013.09.018","article-title":"Enteroendocrine cell types revisited","volume":"13","author":"MS Engelstoft","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmet.2008.11.004","article-title":"A gut feeling for obesity: 7TM sensors on enteroendocrine cells","volume":"8","author":"MS Engelstoft","year":"2008","journal-title":"Cell Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/JOE-08-0453","article-title":"GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis","volume":"201","author":"H Lan","year":"2009","journal-title":"J Endocrinol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1","volume":"88","author":"EM Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1006\/bbrc.2002.6607","article-title":"Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1","volume":"291","author":"SA Hinke","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1464-5491.2009.02748.x","article-title":"Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes","volume":"26","author":"J Cuthbertson","year":"2009","journal-title":"Diabet Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2006.07.043","article-title":"Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1","volume":"547","author":"BD Green","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1464-5491.2005.01461.x","article-title":"Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes","volume":"22","author":"JR Lindsay","year":"2005","journal-title":"Diabet Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/j.1464-5491.2012.03675.x","article-title":"Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus","volume":"29","author":"SK Thondam","year":"2012","journal-title":"Diabet Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1210\/jc.2006-1932","article-title":"The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion","volume":"92","author":"A El-Ouaghlidi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"E1314","DOI":"10.1210\/jc.2011-0038","article-title":"Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome","volume":"96","author":"L Sze","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref40","first-page":"R910","article-title":"GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans","volume":"277","author":"E Naslund","year":"1999","journal-title":"Am J Physiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1210\/en.2011-1485","article-title":"Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell","volume":"152","author":"AJ Mulherin","year":"2011","journal-title":"Endocrinology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/en.2011-1732","article-title":"Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue","volume":"153","author":"GV Sangle","year":"2012","journal-title":"Endocrinology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1463-1326.2012.01587.x","article-title":"Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes","volume":"14","author":"LB Katz","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"ref44","first-page":"A43","article-title":"MBX-2982, a novel oral GPR119 agonist for the treatment of Type 2 Diabetes: Results of single and multiple dose studies","volume":"58","author":"B Roberts","year":"2009","journal-title":"Diabetes"},{"key":"ref45","first-page":"603","article-title":"MBX-2982, a novel GPR119 agonist, shows greater efficacy in patients with the most glucose intolerance: Results of a Phase 1 study with an improved formulation","volume":"59","author":"B Roberts","year":"2010","journal-title":"Diabetes"},{"key":"ref46","first-page":"A84","article-title":"The novel GPR119-recepor agonist PSN821 shows glucose lowering and decreased energy intake in patients with T2DM after 14 days treatment","volume":"60","author":"ML Goodman","year":"2011","journal-title":"Diabetes"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0092494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T20:20:20Z","timestamp":1540326020000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0092494"}},"subtitle":[],"editor":[{"given":"T. Mark","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,3]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0092494","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,3]]}}}